Avience Biomedicals Limited (NSE:AVIENCE)
India · Delayed Price · Currency is INR 346.80
+10.45 (3.11%)
At close: Sep 10, 2026
Avience Biomedicals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 87.53 | 72.91 | 21.52 | 7.76 | 7.13 |
Depreciation & Amortization | 12.22 | 8.59 | 6.17 | 2.09 | 0.97 |
Loss (Gain) From Sale of Assets | -0.04 | -0.09 | -0.07 | - | - |
Provision & Write-off of Bad Debts | 2.35 | - | - | 0.21 | - |
Other Operating Activities | 21.11 | 30.38 | 14.53 | 2.54 | 2.54 |
Change in Accounts Receivable | -40.42 | -91.21 | 19.54 | 7.01 | -20.4 |
Change in Inventory | -41.04 | -6.76 | -53.83 | -20.75 | -11.92 |
Change in Accounts Payable | 22.06 | 17.19 | 24.29 | 10.43 | 0.63 |
Change in Other Net Operating Assets | -4.7 | 2.32 | -22.3 | 6.59 | 1.43 |
Operating Cash Flow | 59.06 | 33.34 | 9.85 | 15.87 | -19.63 |
Operating Cash Flow Growth | 77.16% | 238.46% | -37.94% | - | - |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -134.49 | -93.08 | -38.81 | -16.88 | -8.69 |
Sale of Property, Plant & Equipment | 0.98 | 0.63 | 0.46 | - | - |
Investment in Securities | -0.09 | -2.89 | -1.95 | -2.48 | - |
Other Investing Activities | 0.9 | 0.09 | 0.03 | 0 | -0.18 |
Investing Cash Flow | -132.69 | -95.26 | -40.28 | -19.36 | -8.86 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Short-Term Debt Issued | 28.69 | 44.62 | 1.54 | 1.69 | 17.38 |
Long-Term Debt Issued | 39.08 | 34.93 | 35.96 | - | 1.7 |
Total Debt Issued | 67.77 | 79.55 | 37.5 | 1.69 | 19.08 |
Net Debt Issued (Repaid) | 67.77 | 79.55 | 37.5 | 1.69 | 19.08 |
Issuance of Common Stock | - | 36.05 | - | 5 | 10.25 |
Other Financing Activities | -13.59 | -13.13 | -7.83 | -2.36 | -1.47 |
Financing Cash Flow | 54.18 | 102.47 | 29.67 | 4.33 | 27.86 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Miscellaneous Cash Flow Adjustments | - | - | 1.3 | - | 0 |
Net Cash Flow | -19.45 | 40.54 | 0.55 | 0.84 | -0.63 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -75.42 | -59.75 | -28.96 | -1.01 | -28.31 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Margin | -14.37% | -13.21% | -12.08% | -0.92% | -27.90% |
Free Cash Flow Per Share | -18.71 | -15.75 | -8.82 | -0.38 | -21.05 |
Levered Free Cash Flow | -96.78 | -136.84 | -77.42 | -5.13 | -31.11 |
Unlevered Free Cash Flow | -87.15 | -128.64 | -71.95 | -3.65 | -30.19 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 13.58 | 13.13 | 7.83 | 2.36 | 1.47 |
Cash Income Tax Paid | 28.73 | 7.87 | 1.8 | 1.72 | 1.56 |
Change in Working Capital | -64.1 | -78.45 | -32.3 | 3.28 | -30.26 |